Condition
Ovarian|Melanoma|Renal|Prostate|Colorectal|Endometrial Carcinoma|Cervical Carcinoma|Testicular Cancer|Thyroid Cancer|Small Cell Lung Carcinoma|Mesothelioma|Breast Carcinoma|Esophageal Carcinoma|Gastric Cancer|Pancreatic Carcinoma|Neuroendocrine Cancer|Liver Cancer|Gallbladder Cancer|Biliary Tract Cancer|Anal Carcinoma|Bone Sarcomas|Soft Tissue Sarcomas|Carcinoma of Unknown Origin, Primary
Estimated Enrollment: 12
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: MKC1106-PP-001
Study First Received: January 12, 2007
Last Updated: August 2, 2010
Estimated Primary Completion Date: September 2009
Primary Outcome Measures:
To determine the immunologic response to the treatment with MKC1106-PP regimen and 2) to determine the safety and adverse event profile of MKC1106-PP|to determine the blood plasmid levels by PCR analysis|measure cytokine levels|to describe any objective tumor responses to the treatment with MKC1106-PP
Sponsors and Collaborators:
Mannkind Corporation
Website Link: https://ClinicalTrials.gov/show/NCT00423254
